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Objectives. To assess the beneﬁcial and adverse eﬀects of Xiaoyaosan for depression. Search Strategy. Electronic databases were
searched until December 2009. Inclusion Criteria. We included randomized clinical trials testing Xiaoyaosan against placebo,
antidepressants, or combined with antidepressants against antidepressants alone. Data Extraction and Analyses. Study selection,
dataextraction,qualityassessment,anddataanalyseswereconductedaccordingtotheCochranestandards.Results. 26randomized
trials (involving 1837 patients) were included and the methodological quality was evaluated as generally low. The pooled results
showed that Xiaoyaosan combined with antidepressants was more eﬀective in comprehensive eﬀect, the score of HAMD and
the score of SDS compared with antidepressants alone. Xiaoyaosan was superior to antidepressants for the score of HAMD.
However, Xiaoyaosan was not diﬀerent from placebo for the score of SDS. There was no adverse eﬀects reported in the trials
from Xiaoyaosan. Conclusions. Xiaoyaosan appears to be eﬀective on improving symptoms in patients with depression. However,
due to poor methodological quality in the majority of included trials, the potential beneﬁt from Xiaoyaosan need to be conﬁrmed
in rigorous trials and the design and reporting of trials should follow international standards.
1.Introduction
Depression is a common mental disorder that presents
with depressed mood, loss of interest or pleasure, feelings
of guilt or low self-worth, disturbed sleep or appetite,
insomnia or hypersomnia, fatigue or loss of energy, and
poor concentration or diﬃculty making decisions. These
problems can become chronic or recurrent and lead to
substantial impairments in an individual’s ability to take care
of his or her everyday responsibilities.
Depression is recognized as a major public health
problem, which has a substantial impact on individuals and
society. Depressive disorders are common in the general
population. It aﬀecting about 121 million people worldwide.
At its worst, depression can lead to suicide, a tragic fatality
associated with the loss of about 850000 thousand lives
every year. Depression is the leading cause of disability
as measured by Years Lived with Disability (YLD). The
World Health Organization has described depression as an
“unseen burden” [1, 2]. It was the 4th leading contributor
to the global burden of disease when measured by Disability
Adjusted Life Years (DALYs) in 2000. By the year 2020,
depression is projected to reach 2nd place of the ranking of
DALYs calculated for all ages in both sexes. Today, depression
is already the 2nd cause of DALYs in the age category 15–
44 years for both sexes combined. Mood disorders have been
shown to have a greater impact on quality of life compared
withconditionssuchashypertensionandcardiacdisease[3].
In China, depression is now one of the top three public
health problems. Statistics show that 5 per cent of Chinese
people suﬀer from the disease and 13 out of 1,000 Chinese
have mental health issues [4]. Until 2003, China has over
26 million depression patients, for which discrimination and
neglect are the two major obstacles to curing them, thus
incurring an annual loss of over 64 billion yuan, according
to a reserved estimation made at the Seminar on Attention
to the Socio-Economic Burden of Depression held [5].2 Evidence-Based Complementary and Alternative Medicine
Depression is most commonly treated with antidepres-
sants in primary care [6]. In addition, there are other kind of
psychological interventions, such as cognitive behavior ther-
apies, interpersonal therapy, psychotherapy, and counseling.
The most widely prescribed antidepressants come from a
class of medications known as selective serotonin reuptake
inhibitors (SSRIs). Besides of that “atypical” antidepressants,
the older tricyclic antidepressants and monoamine oxidase
inhibitors (MAOIs). The common side eﬀects include sex-
ual problems, drowsiness, fatigue, sleep diﬃculties, nausea
weight gain, nervousness, dry mouth, and blurred vision.
Stop taking drugs abruptly may cause “antidepressant dis-
continuation syndrome” such as spells, extreme restlessness,
dizziness, fatigue, and aches and pains.
The Xiaoyaosan (XYS) decoction containing eight com-
monly used herbs (Bupleurum root, Chinese angelica root,
white peony root, poria, bighead atractylodes rhizome,
roasted ginger, prepared licorice root, menthol and pepper-
min) been used for treatment of mental disorders such as
depression for centuries in China. The mechanism of the
descriptionmaybesoothingtheliver,invigoratingthespleen,
nourishing the blood to restore the normal menstruation,
and clearing away the liver ﬁre due to blood deﬁciency.
Biochemically, the XYS decoction also reversed CIS-induced
decreases in brain-derived neurotrophic factor (BDNF) and
increases in tyroxine hydroxylase (TrkB), and neurotrophin
3 (NT-3) in the frontal cortex, and the hippocampal CA
subregion.
Currently, xiaoyaosan used alone or integrated with
antidepressants has been widely used as an alternative and
eﬀective method for the treatment of depression in China.
Many clinical studies reported the eﬀectiveness ranging from
case reports and case series to controlled observational
studies and randomized clinical trials, but the evidence for
its eﬀect is not clear. The present paper aims to evaluate
the beneﬁcial and harmful eﬀects of xiaoyaosan (wan) for
treatment of depression in randomized trials.
2. Methods
2.1. Database and Search Strategies. Literature searches
were conducted in National Knowledge Infrastructure
(1999–2009), VIP Database for Chinese Technical Period-
icals (1989–2009), Chinese Biomedical Literature Database
(1995–2009), PubMed (1950–2009), and Cochrane library
(Issue 3, 2009) and searched the reference list of retrieved
papers. All of those searches ended the end of November
2009. We used the search terms “depression,” “xiaoyaowan,”
“xiaoyaosan,” and “xiaoyaotang.” Various combinations of
the terms were used, depending on the database searched.
The bibliographies of included studies were searched for
additional references.
2.2. Inclusion Criteria. All the parallel randomized con-
trolled trials (RCTs) of all the prescriptions based on
“xiaoyaosan” including pills, powder, decoction dosage form
compared with antidepressants in patients with depression
were included. RCTs combined xiaoyansan with antidepres-
sants compared with antidepressants and all the modiﬁed
xiaoyaosan formula were included as well. There were
no restrictions on population characteristics, language and
publication type.
OutcomemeasuresincludeClinicalComprehensiveEﬀect,
Hamilton depression scale (HAMD) scores, self-rating
depression scale (SDS) scores, self-rating anxiety scale (SAS)
scores, Hamilton Anxiety Scale (HAMA), scores, clinical
global impression (CGI) scores, the scale for TCM syndrome
and symptom diﬀerentiation (TCM-SSD) scores and so
forth, the criteria “recover, signiﬁcant eﬀective, eﬀective, or
not eﬀective” was also include in the outcome measurement.
Duplicatedpublicationsreporting thesamegroupsofpartic-
ipants were excluded.
2.3. Data Extraction and Quality Assessment. Two authors (J.
P. Liu and Y. Q. Zhang) extracted the data from the included
trialsindependently.Themethodologicalqualityoftrialswas
assessed using the 6 criteria 6 election bias (study design,
confounders, blinding, data collection methods, withdrawals
and dropouts) to following 3 categories: Category A (strong
quality): four strong ratings with no weak ratings above.
Category B (moderate quality): less than four strong ratings
andoneweakrating.CategoryC(weakquality):twoormore
weak ratings.
Quality assessment of included randomized controlled
trials: sequence generation, allocation concealment, blinding
of participants personnel and outcome assessors, incom-
plete outcome data, selective outcome reporting, and other
sources of bias.
2.4. Data Synthesis. The statistical package (RevMan 4.3.2)
was used for data analyses, which was provided by The
Cochrane Collaboration. Dichotomous data were presented
as risk ratio (RR) and continuous outcomes as mean
diﬀerence (MD), both with 95% conﬁdence interval (CI).
Meta-analysis was performed if the intervention, control,
and outcome were the same or similar. The statistical
heterogeneity was presented as signiﬁcant when I square (I2)
is over 50% or P<0.1. Random eﬀect model was used for
the meta-analysis if there was signiﬁcant heterogeneity (I2 >
50%)andﬁxedeﬀectmodelwasusedwhentheheterogeneity
was not signiﬁcant (I2 < 50%) [7].
3. Result
3.1. Description of Included Trials. After primary search of
5 databases, 263 trials were screen out from electronic and
manual searches (Figure 1), and the majority were excluded
due to obvious ineligibility which including irrelevant
titles and abstract (some papers being found from more
than one database). 141 trials with full text papers were
retrieved. 122 RCTs were excluded because of reporting
the depression complicated with other disease such as
stroke and postpartum, 60 trials were excluded because of
duplicated publication, 22 trials were excluded due to the
animal studies, and the rest 41 trials were noncontrolledEvidence-Based Complementary and Alternative Medicine 3
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N = 52
CNKI
N = 173
Cochrane library
N = 8
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Total
N = 263
Full text
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Repetitions n = 60
Animal study n = 22
Case report, case series
traditional review n = 41
114 studies excluded based
on the inclusion criteria
Title, abstract
PubMed
N = 13
Figure 1: Study selection process.
clinical trials including case report, case series traditional
review. 114 out of the rest of 140 articles were excluded
based on the inclusion criteria. The treatment for depressive
neurosis, bipolar disorders, and depression in patients with
psychological stress insomnia were excluded. In the end, 26
RCTs were reviewed. The characteristics of 26 randomized
trials are summarized in Table 1.
The 26 RCTs involved 1837 patients with depression.
T h e r ew a saw i d ev a r i a t i o ni nt h ea g eo fs u b j e c t s( 1 7 – 8 0
years). Twenty-six (26) trials speciﬁed six diagnostic criteria,
four trials [7, 17, 22, 25, 31, 32] used the China classiﬁcation
and diagnostic criteria for mental disorder (second edition
CCMD-2-R) alone, six [8, 9, 11, 18, 20, 24, 26–28, 30]
trials used the third edition (CCMD-3) alone, three trials
combined international classiﬁcation on the diagnosis of
depression (ICD-10) with CCMD-2-R [19] or CCMD-3
[12, 15], one trials [21] combined the depression standard
in “internal medicine of Chinese medicine” and CCMD-
3 together, one trial [16] used CCMD-3 and aﬀective
disorder in the western medicine and Chinese medicine
classiﬁcation and diagnostic criteria on depression breaks
out, two trials [10, 29] used CCMD-3 and the diagnostic
criteria of Chinese medicine on depression and stagnation of
liver qi, one trial [23] used CCMD-3 and depression of liver-
qi stagnation and spleen deﬁciency, the last trial [13] used
the depression standard in TCM on liver-qi stagnation and
spleen deﬁciency.
The interventions included all the prescriptions based
on “xiaoyaosan” including pills, powder, decoction dosage
form alone, with Maprotiline placebo or with antide-
pressants. The controls included antidepressants alone or
the combination of danzhiXiaoyaosan (DXS) placebo and
antidepressants. Eight trials investigated the prescriptions
based on “xiaoyaosan” using alone [9, 17–19, 23, 30]o r
plus placebo [12, 15] versus antidepressants, one three-arm
trial and the rest sixteen trials [7, 8, 10, 11, 13, 14, 16, 20–
22, 24–29, 31, 32] compared the prescriptions based on
“xiaoyaosan” plus antidepressants versus antidepressants.
The total treatment duration ranged from 30 days to 3
month. The variable prescriptions are presented in Table 1.
The diﬀerent composition of formula Xiaoyaosan are pre-
sented in Table 2. Nineteen (19) of the 26 trials used the
hamiltondepressionscale(HAMD)astheoutcomemeasure,
other 4 kinds of scales including self-rating depression
scale (SDS), self-rating anxiety scale (SAS), the scale for
TCM syndrome and symptom diﬀerentiation (TCM-SSD),
the hamilton anxiety scale (HAMA) were also be used.
Side eﬀect was evaluated by asberg side eﬀect scale and
treatment-emergent symptom side eﬀect (TESS) scale or
described in details. Eleven (11) trials used four classes
to evaluate treatment eﬀects including cure, signiﬁcant
eﬀective, eﬀective, ineﬀective, while ten (10) trials used three
classes (except of cure) according to the scores reducing rate.
3.2. Methodological Quality of Included Trials. Six [10, 12,
15, 16, 23, 26] out of 26 trials (23.08%) were evaluated as
strong quality, the rest of 20 trials (76.928%) were evaluated
as moderate quality. The majority of the included trials were
assessed to be moderate methodological quality. The sample
size of including trials varied from 24 to 200 patients. None
of the 26 trials reported sample size calculation. Ten trials
described the randomization procedure, six [10, 12, 15, 16,
23,26]trialsusedrandomnumbertable,fourtrials[8,17,25,
30] used visiting time to realize the randomization. One trial
[23] used opaque envelopes to allocate concealment. Only4 Evidence-Based Complementary and Alternative Medicine
Table 1: Characteristics and methodological quality of included studies.
Study ID Sample Diagnosis
standard Intervention Control Course
(week)
Followup
(month) Outcome measure
Du et al.
[8] 120 CCMD-3 xiaoyao pill plus
ﬂuoxetine
amitriptyline
paroxetine 6–8 HAMD and TESS
score, side eﬀect
Huang and
Gan [9] 69 ICD-10 Shugan jieyu
formula amitriptyline 6 clinical eﬀect, side
eﬀect
Huo et al.
[10] 72 CCMD-3
danzhi xiaoyao
decoction plus
ﬂuoxetine
ﬂuoxetine 6
clinical eﬀect,
HAMD, HAMA
and CJI score, side
eﬀect
J. Li et al.
[11] 60 CCMD-3 xiaoyao pill plus
imipramine imipramine 8
clinical eﬀect,
HAMD score, side
eﬀect
Y. J. Li et
al. [12] 66 CCMD-3,
ICD-10
danzhixiaoyao
powder maprotiline 6
HAMD score,
5-HT, NE, EDNF,
CORT, IL-6, IL-1β
H. Li et al.
[13] 80 Unclear xiaoyao powder
plus ﬂuoxetine ﬂuoxetine 6 12
clinical eﬀect,
HAMD, SDS score,
side eﬀect
Liu and
Chen 2007
[14]
78
“practice
of internal
medicine”-
3
danzhixiaoyao
powder plus
amitriptyline
amitriptyline 8 clinical eﬀect,
HAMD score
Luo et al.
2006 [15] 66 CCMD-3,
ICD-10
danzhixiaoyao
powder maprotiline 6
symptoms, clinical
eﬀect, HAMD,
SDS, SAS and
Asberg score, side
eﬀect
Ma 2007
[16] 60 CCMD-3 xiaoyao pill plus
citalopram citalopram 8 12
clinical eﬀect,
HAMD and Tess
score, side eﬀect
C. Y. Wang
et al. 2004
[17]
200 CCMD-2-
R
guipi xiaoyao
pill venlafaxine 4 clinical eﬀect, SDS
score, side eﬀect
R. C.
Wang 2008
[18]
60 CCMD-3 modiﬁedxiaoyao
powder amitriptyline 6
clinical eﬀect,
HAMD score, side
eﬀect
T. Y. Wang
2001 [19] 61
CCMD-2-
R
ICD-10
danzhixiaoyao
decoction ﬂuoxetine 6 clinical eﬀect, SDS
score, side eﬀect
W. A.
Wang et al.
2005 [20]
68 CCMD-3 xiaoyao pill plus
doxepin ﬂuoxetine 6
clinical eﬀect,
HAMD and
HAMA score, side
eﬀect
Y. Wang
and Liu
[21]
60 CCMD-3
danzhixiaoyao
powder plus
ﬂuoxetine
ﬂuoxetine 8
clinical eﬀect,
HAMD and
CGI-SI score, side
eﬀect
Wei et al.
1999 [22] 60 CCMD-2-
R
xiaoyao powder
plus
amitriptyline
amitriptyline 4 clinical eﬀect
Xian et al.
[23] 60 CCMD-3 xiaoyao powder ﬂuoxetine 6
symptoms, clinical
eﬀect, HAMD
score
Xiao [24] 66 CCMD-3
danzhixiaoyao
powder plus
clomipramine
clomipramine 8 clinical eﬀectEvidence-Based Complementary and Alternative Medicine 5
Table 1: Continued.
Study ID Sample Diagnosis
standard Intervention Control Course
(week)
Followup
(month) Outcome measure
Yang and
Xie [25] 58 CCMD-2
xiaoyao powder
plus
amitriptyline or
clomipramine
amitriptyline or
clomipramine 12 clinical eﬀect, TESS
score, side eﬀect
Yang et al.
[26] 64 CCMD-3
modiﬁed
xiaoyao pill plus
amitriptyline
ﬂuoxetine 12 3
clinical eﬀect,
HAMD score, side
eﬀect
Zhai et al.
[7] 24 CCMD-2-
R
xiaoyao powder
plus doxepin doxepin 8
clinical eﬀect,
HAMD and TESS
score, side eﬀect
Zhang et
al. [27] 59 CCMD-3 xiaoyao pill plus
ﬂuoxetine ﬂuoxetine 6
clinical eﬀect,
HAMD and TESS
score, side eﬀect
Zhang
[28] 50 CCMD-3 xiaoyao pill plus
ﬂuoxetine ﬂuoxetine 6 HAMD score, side
eﬀect
Zhao and
Jiang [29] 66 CCMD-3
modiﬁed
xiaoyao powder
plus
amitriptyline
amitriptyline 12
symptoms, clinical
eﬀect, HAMD
score, side eﬀect
Zhou and
Li [30] 90 CCMD-3 xiaoyao powder ﬂuoxetine 8
symptoms, clinical
eﬀect, HAMD and
SDS score, side
eﬀect
Zhu [31] 60 CCMD-2 xiaoyao pill plus
venlafaxine venlafaxine 10 HAMD score, side
eﬀect
Zhu and Li
[32] 60 CCMD-2
xiaoyao powder
plus
amitriptyline
amitriptyline 8 clinical eﬀect, side
eﬀect
four [12, 15, 23, 27] of the 26 trials employed a blinding
procedure: three of them using patients blinding, doctors
blinding, and assessors blinding, and the other one [27]
mentioned single-blind without further details. Seven trials
[8, 10–12, 15, 21, 25] reported the withdrawals/dropouts
information. Three trials [13, 16, 26]m e n t i o n e df o l l o w - u p ,
and neither of them used intention to treat method. The
reporting quality of 26 trials according to quality assessment
tool for quantitative studies varied among diﬀerent trials
(Table 3).
3.3. Eﬀect of the Interventions (Tables 4–6)
3.3.1. “Xiaoyaosan” versus Antidepressants (Western Medi-
cine). Eight [9, 12, 15, 17–19, 23, 30]t r i a l sc o m p a r e d
xiaoyaosan with antidepressants.
Clinical Comprehensive Eﬀect. Seven of the eight trials used
clinical comprehensive eﬀect to evaluate the outcome. Five
trials [9, 15, 18, 23, 30] used the percentage of HAMD scores
reduced rate to measure the outcome: cure (HAMD scores
reduced rate more than 75%), signiﬁcant eﬀective (HAMD
scores reduced rate between 51% and 75%), eﬀective
(HAMD scores reduced rate from 25 to 50%) and ineﬀective
(HAMD scores reduced rate less than 25%). None of the ﬁve
trials showed signiﬁcant diﬀerence between treatment and
control group on the four criteria outcome measurement
Two [17, 19] trials compared the eﬀectiveness using the
three criteria outcome measurement: signiﬁcant eﬀective
(SDS scores reduced rate ≥ 50%), eﬀective (50 > SDS scores
reduced rate ≥ 30%), not eﬀective (SDS scores reduced
rate < 30%). The Total eﬀective rate is the combination
of “cure”, “signiﬁcant eﬀective “and” eﬀective rate”. We
put these two diﬀerent kinds of measurements together
to evaluate the general eﬀectiveness. The meta-analysis
showed no signiﬁcant diﬀerence between xiaoyaosan and
antidepressants on the Total eﬀective rate (RR: 1.05 [1.00,
1.11]; P = 0.07) (Table 4).
HAMD Scores Decrease. Meanwhile four trials [12, 15, 18,
30]reportedtherearenosigniﬁcantdiﬀerenceontheHAMD
scores decrease nor on the HAMD scores reduced rate [15]
after 6 weeks treatment. Meta-analysis of three trials showed
the same result in the ﬁxed eﬀects model (WMD: 0.59
[−0.51, 1.70]; P = 0.29) and random eﬀects model (WMD:
0.43 [−2.14, 2.99]; P = 0.74) with signiﬁcant heterogeneity
(I2 = 68.7%) (Table 5).
SDS Scores Decrease. Four trails [15, 17, 19, 30] reported the
SDS scores decreasing. Meta-analysis of four trials showed
signiﬁcant diﬀe r e n c ei nf a v o ro fm o d i ﬁ e dx i a o y a op o w d e ro r6 Evidence-Based Complementary and Alternative Medicine
Table 2: Composition of formula.
ID Formulation Composition of formula
Du et al. [8] pill Chinese patent medicine
Huang and
Gan [9] decoction
Bupleuri 10g, Paeoniae lactiﬂorae 15g, Poriae cocos pararadicis 30g, Atractylodis macrocephalae 15g,
Moutan radicis 10g, Curcumae 10g, Angelicae sinensis 15g, Menthae haplocalycis 10g, Tritici aestivi
levis 30g, Polygoni multiﬂory 30g, Pseudostellariae heterophyllae 20g. Menstrual period remove Moutan
radicis, Pseudostellariae heterophyllae, Menthae haplocalycis, plus Ligustici chuanxiong 10g, Persicae 10g,
Leonuri heterophylli 30g, Guanzhong 10g, typhae 10g, Trogopteri seu pteromi 10g; Follicular phase
remove Moutan radicis, Menthae haplocalycis, plus Cervi 15g, Epimedii 15g, Chrysanthemi indici 15g,
Lycii 15g; Luteal phase plus Gardeniae jasminoidis 10g, Ligustri lucidi 20g, Liquidam baris taiwanianae
15g, Cyperi rotundi 10g, Rhapontici seu echinops 10g
Huo et al.
[10] decoction
Bupleuri 10g, Paeoniae lactiﬂorae 12g, Angelicae sinensis 12g, Poriae cocos 20g, Atractylodis macro-
cephalae 10g, Moutan radicis 12g, Gradeniae jasminodidis 10g, Curcumae l2g, Acori graminei 10g,
Fructus aurantii 10g, Draconis 30g, Ostreae 30g, Polygalae tenuifoliae 12g, Cizyphi spinosae 30g, Tritici
aestivi levis 30g,Glycyrrhizae uralensis 10g,Zizyphi jujubae 5.Bloodstasis plusLigustici chuanxiong 12g,
Salviae milgiorrhizae 20∼30g; Phelgm and dampness plus Citrireticulatae 10g, Pinelliae ternatae 10g; Yin
deﬁciency plus Lilii 30g, Anemarrhenae asphodeloibis 10g; Qi deﬁciency remove Gradeniae jasminodidis,
plus Pseudostellariae heterophyllae 15g; Astriction plus Cannabis sativae 10g or Radix et rhizome 10g
Li et al. [11] pill Chinese patent medicine
Li et al. 2007
[12] powder Chinesepatent medicine(bupleuri,angelicae sinensis,poriaecocos,atractylodismacrocephalae, gradeniae
jasminodidis, moutan radicis)
Li et al. [13]d e c o c t i o n Bupleuri 15g, Angelicae sinensis 15g, Atractylodis macrocephalae 15g, Paeoniae lactiﬂorae 10g, Poriae
cocos 10g, Menthae haplocalycis 6g, Glycyrrhizae uralensis 6g
Liu and Chen
[14] decoction
Bupleuri 8g, Gradeniae jasminodidis 6g, Ligustici chuanxiong 6g, Glycyrrhizae uralensis 6g, Moutan
radicis 10g, Taeoniae rubrae 10g, Atractylodis macrocephalae 10g, Draconis 30g, Ostreae 30g, Poriae
cocos 15g. Liver qi stagnation and abdominal distention plus Aucklandiae lappae 10g, Citri reticulatae
10g, Cyperi rotundi 6g; Insomnia plus Albizziae julibrissin 15g, Polygoni multiﬂory 15g, Poriae cocos
pararadicis 15g, Polygalae tenuifoliae 10g; Cizyphi spinosae 10g; Spleen and stomach deﬁciency plus
Pseudostellariae heterophyllae 10g, Citri reticulatae 10g; Phlegm and dampness and no appetite plus
Pinelliae ternatae 10g, Bambusae in taeniis 10g, Citri reticulatae 10g, Amomi 6g
Luo et al. [15]p o w d e r Bupleuri, Angelicae sinensis, Paeoniae lactiﬂorae, Poriae cocos, Atractylodis macrocephalae, Moutan
radicis, Gradeniae jasminodidis
Ma [16] pill Chinese patent medicine
Wang et al.
[17] pill
Bupleuri,Astragalimembranacei,Codonotsitispilosulae,Angelicaesinensis,Paeoniaelactiﬂorae,Rehman-
niae glutinosae, Artemisiae yinchenhao, Atractylodis macrocephalae, Poriae cocos, Aucklandiae lappae,
Cizyphi spinosae, Polygalae tenuifoliae, Schisandrne chinensis, Acori graminei, Moutan radicis, Moschus,
Menthae haplocalycis, Glycyrrhizae uralensis
Wang [18]d e c o c t i o n
Bupleuri 12g, Angelicae sinensis 20g, Paeoniae lactiﬂorae 12g, Atractylodis macrocephalae 12g, Lilii
15g, Albizziae julibrissin 15g, Citri aurantii 10g, Pinelliae ternatae 12g, Gradeniae jasminodidis 10g,
Scutellariae baicalensis 10g, Bambusae textillis 15g, Curcumae 12g, Acori graminei 12g, Glycyrrhizae
uralensis 6g, Zizyphi jujubae 6
Wang [19]d e c o c t i o n
Bupleuri 10g, Paeoniae lactiﬂorae 12g, Angelicae sinensis 12g, Poriae cocos 20g, Atractylodis macro-
cephalae 10g, Moutan radicis 12g, Gradeniae jasminodidis 10g, Curcumae 12g, Acori graminei 10g,
Fructus aurantii 10g, Draconis 30g, Ostreae 30g, Polygalae tenuifoliae 12g, Cizyphi spinosae 30g, Tritici
aestivi levis 30g,Glycyrrhizae uralensis 10g,Zizyphi jujubae 5.Bloodstasis plusLigustici chuanxiong 12g,
Salviae milgiorrhizae 20–30g; Phlegm and dampness plus Citri reticulatae 10g, Pinelliae ternatae 10g; Yin
deﬁciency plus Lilii 30g, Anemarrhenae asphodeloibis 10g; Qi deﬁciency remove Gradeniae jasminodidis,
plus Pseudostellariae heterophyllae 15g; Astriction plus Cannabis sativae 10g or Radix et rhizome 10g
Wang et al.
[20] pill Chinese patent medicine
Wang and
Liu [21] decoction
Angelicae sinensis 10g, Paeoniae lactiﬂorae 12g, Bupleuri 12g, Atractylodis macrocephalae 10g, Poriae
cocos 12g, Zingiberis oﬃcinalis recens 10g, Glycyrrhizae uralensis 10g, Moutan radicis 10g, Gradeniae
jasminodidis 10g
Wei et al. [22]d e c o c t i o n
Qi stagnation and blood stasis plus Salviae milgiorrhizae, Cyperi rotundi, Linger strychnifoliae, Ligustici
chuanxiong, Taeoniae rubrae; Qi stagnation leading to ﬁre plus Salviae milgiorrhizae, Gardeniae
jasminoidis; Qi and blood deﬁciency plus Codonotsitis pilosulae, Astragali membranacei, Rehmanniae
glutinosae conquitae; Palpitation plus Cizyphi spinosae, Draconis, ostreae, Polygalae tenuifoliae, Biotae
orientalin; Spleen and kidney deﬁciency plus Morindae oﬃcinalis, Curculiginis orchioidis, Epimedii,
Zingberis oﬃcinalis, Aconiticarmichaeli praeparata, Corneum gigeriae galliEvidence-Based Complementary and Alternative Medicine 7
Table 2: Continued.
ID Formulation Composition of formula
Xian et al.
[23] decoction Angelicae sinensis, Paeoniae lactiﬂorae, Poriae cocos, Atractylodis macrocephalae, Menthae haplocalycis,
Bupleuri, Zingiberis oﬃcinalis recens, Glycyrrhizae uralensis
Xiao [24]d e c o c t i o n
Bupleuri 30g, Menthae haplocalycis 12g, Atractylodis macrocephalae 10g, Poriae cocos 15g, Moutan
radicis 12g, Gradeniae jasminodidis 12g, Angelicae sinensis 12g, Paeoniae lactiﬂorae 10g, Zingiberis
oﬃcinalis recens, Glycyrrhizae uralensis 6g. Blood stasis Ligustici chuanxiong 12g; Phelgm and dampness
plus Citri reticulatae 10g, Pinelliae ternatae 10g; Yin deﬁciency plus Anemarrhenae asphodeloibis 10g;
Qi deﬁciency plus Pseudostellariae heterophyllae 15g; Astriction plus Cannabis sativae 10g or Radix et
rhizome l0g
Yang and Xie
[25] decoction
Bupleuril5g,Atractylodismacrocephalael0g,Paeoniaelactiﬂorael0g,Angelicaesinensisl0g,Poliaecocos
l0g. Menthae haplocalycis 6g, Glycyrrhizae uralensis 6g. Qi stagnation leading to ﬁre plus Gradeniae
jasminodidis, Moutan radicis, Fructus aurantii; Heart and spleen deﬁciency plus Codonotsitis pilosulae,
Astragali membranacei, Polygalae tenuifoliae, Dioscoreae oppositae; Phlegm and Qi stagnation plus
Trichosanthis, Pinelliae ternatae, Madnoliae oﬃcinalis; Blood stasis plus Persicae, Salviae milgiorrhizae,
Ligustici chuanxiong; Insomnia plus Cizyphi spinosae, Polygoni multiﬂori, Succinum
Yang et al.
[26] pill
Bupleuri, Angelicae sinensis, Paeoniae lactiﬂorae, Poriae cocos, Atractylodis macrocephalae, Moutan
radicis, Gradeniae jasminodidis, Menthae haplocalycis, Glycyrrhizae uralensis
Zhai et al. [7] pill Chinese patent medicine
Zhang et al.
[27] pill
Bupleuri, Angelicae sinensis, Paeoniae lactiﬂorae, Atractylodis macrocephalae, Poriae cocos, Menthae
haplocalycis, Zingiberis oﬃcinalis recens, Glycyrrhizae uralensis
Zhang [28] pill Chinese patent medicine
Zhao and
Jiang [29] decoction
Bupleuri 15g, Angelicae sinensis 15g, Paeoniae lactiﬂorae 15g, Atractylodis macrocephalae 15g, Poriae
cocos 15g, Moutan radicis 10g, Gradeniae jasminodidis 10g, Glycyrrhizae uralensis 10g, Menthae
haplocalycis 10g, Zingiberis oﬃc i n a l i sr e c e n s1 0g
Zhou and Li
[30] decoction
Bupleuri 12g, Angelicae sinensis 12g, Atractylodis macrocephalae 9g, Poriae cocos 15g, Paeoniae
lactiﬂorae 12g, Cizyphi spinosae 15g, Salviae milgiorrhizae 30g, Ligustici chuanxiong 12g, Carthami
tinctolii 12g, Persicae 9g, Gradeniae jasminodidis 12g, Citri reticulatae viride 9g, Glycyrrhizae uralensis
6g
Zhu [31] pill Chinese patent medicine
Zhu and Li
[32] decoction
Heart and spleen deﬁciency plus Codonotsitis pilosulae, Astragali membranacei, Salviae milgiorrhizae,
Polygalae tenuifoliae, Cizyphi spinosae, Asini. liver and kidney yin deﬁciency plus Draconis, Ostreae,
Amydae sinensis, Asinilycii, Moutan radicis, Gradeniae jasminodidis. Liver qi stagnation plus Curcumae,
Citri sarcodactylis, Citri reticulatae, Trichosanthis, Massa fermentata, Agastaches seu pogostemi, Eupatorii
fortunei. Spleen and kidney yang deﬁciency plus Cinnamomi cassiae, Rehmanniae glutinosae conquitae,
Corni oﬃcinalis, Schisandrne chinensis, Acori graminei
decoctioncomparetoantidepressants(WMD: −3.97[−5.52,
−2.41]; P< 0.00001) (Table 6).
Other Outcomes (TCM-SSD Scores, SAS Scores, 5-HT, BDNF,
etc.) One trial [15] showed that there are no signiﬁcant
diﬀerences on TCM-SSD and SAS scores. One trial [12]
showed that after 6 weeks of treatment, the serum level of 5-
hydroxytryptamine (5-HT) and brain-derived neurotrophic
factor (BDNF) increased (P<0.01) and the Interleukin-
6 (IL-6) level decreased in both groups without signiﬁcant
diﬀerence between two groups, the cortisol (CORT) level
reduced signiﬁcantly in the DXP group compared to Mapro-
tiline group.
3.3.2. “Xiaoyaosan” Plus Antidepressants versus Antidepres-
sants. Seventeen trials [7, 10, 11, 13, 14, 16, 20–22, 24–29,
31,32]comparedthecombinationofxiaoyaosanormodiﬁed
xiaoyaosan plus antidepressants with antidepressants.
Clinical Comprehensive Eﬀect. Meta-analysis of fourteen
trials showed signiﬁcant diﬀerence in favor of combination
grouponclinicalcomprehensiveeﬀect(RR:1.10[1.04,1.17];
P = 0.0007) (Table 4).
HAMD Scores Decrease. Fourteen trials reported the HAMD
scores decrease. The meta-analysis of ﬁfteen trials showed
there are signiﬁcant beneﬁcial eﬀect on the combination
group compare to the antidepressants using alone both in
the ﬁxed eﬀects model (WMD: −0.51 [−0.71, −0.31]; P<
0.0001) and random eﬀects model (WMD: −0.69 [−1.25,
−0.13]; P = 0.02) with signiﬁcant heterogeneity (I2 =
76.3%).
SDS Scores Decrease. One trial [13] showed signiﬁcant
beneﬁt on SDS scores decreased in favor of combination
group after 6 (MD: −3.6 [−4.65, −2.55]; P<0.00001) weeks
treatment (Table 6).8 Evidence-Based Complementary and Alternative Medicine
Table 3: Quality assessment of included randomized controlled trials.
Included
trials
Sequence
generation
Allocation
concealment
Blinding of
participants
personnel and
outcome
assessors
Incomplete
outcome data
Selective
outcome
reporting
Other
sourcesof bias Risk of bias
Du et al.
[8] Unclear Unclear Unclear Yes No Unclear High
Huang and
Gan [9] Unclear Unclear Unclear No No Unclear High
Huo et al.
[10]
Table of
random
number
Unclear Unclear No No Unclear Unclear
J. Li et al.
[11] Unclear Unclear Unclear Yes No Unclear Unclear
Liu and
Chen [14] Unclear Unclear Double blind Yes No Unclear Unclear
Li et al.
[13] Unclear Unclear Unclear Yes No Unclear High
Liu and
Chen [14] Unclear Unclear Unclear No No Unclear High
Luo et al.
[15]
Table of
random
number
Unclear Double blind Yes No Unclear Unclear
Ma [16]
Table of
random
number
Unclear Unclear Yes Yes Unclear Unclear
Wang et al.
[17] Unclear Unclear Unclear No No Unclear High
Wang [18] Unclear Unclear Unclear No No Unclear High
Wang [19] Unclear Unclear Unclear No No Unclear High
Wang et al.
[20] Unclear Unclear Unclear No Yes Unclear High
Wang and
Liu [21] Unclear Unclear Unclear No Yes Unclear High
Wei et al.
[22] Unclear Unclear Unclear No Yes Unclear High
Xian et al.
[23]
Table of
random
number
Yes Unclear No Yes Unclear Unclear
Xiao [24] Unclear Unclear Unclear No No Unclear High
Yang and
Xie [25] Unclear Unclear Unclear No Yes Unclear High
Yang et al.
[26]
Table of
random
number
Unclear Unclear No No Unclear Unclear
Zhai et al.
[7] Unclear Unclear Unclear No No Unclear High
Zhang et
al. [27] Unclear Unclear Single-blind No No Unclear Unclear
Zhang
[28] Unclear Unclear Unclear No No Unclear High
Zhao and
Jiang [29] Unclear Unclear Unclear No No Unclear High
Zhou and
Li [30] Unclear Unclear Unclear No No Unclear High
Zhu [31] Unclear Unclear Unclear No No Unclear High
Zhu and Li
[32] Unclear Unclear Unclear No No Unclear HighEvidence-Based Complementary and Alternative Medicine 9
Table 4: Analyses of clinical comprehensive eﬀect.
Trials
Intervention
(n/N) Control (n/N) RR [95% CI] P Value
Xiaoyao powder versus antidepressants
Xiaoyao powder versus amitriptyline 1 41/42 25/27 1.05 [0.94, 1.18] 0.37
Danzhi Xiaoyao powder versus
maprotiline 1 28/32 30/31 0.90 [0.78, 1.05] 0.18
Guipi Xiaoyao powder versus
venlafaxine 1 94/100 86/100 1.09 [1.00, 1.20] 0.06
Modiﬁed Xiaoyao powder versus
amitriptyline 1 29/30 28/30 1.04 [0.92, 1.16] 0.55
Danzyhih Xiaoyao decoction versus
ﬂuoxetine 1 29/34 22/27 1.05 [0.83, 1.31] 0.69
Xiaoyao powder versus ﬂuoxetine 2 66/75 61/75 1.08 [0.94, 1.24] 0.25
Meta-Analysis 7 287/313 252/290 1.05 [1.00, 1.11] 0.07
Xioayao powder plus antidepressants
versus antidepressants
Xiaoyao pills/powder plus
amitriptyline versus amitriptyline 2 56/60 45/60 1.24 [1.06, 1.46] 0.008
Danzhi Xiaoyao decoction/powder
plus ﬂuoxetine versus ﬂuoxetine 2 51/66 38/66 1.34 [1.05, 1.72] 0.02
Xiaoyao pills plus imipramine versus
imipramine 1 26/30 25/29 1.01 [0.82, 1.23] 0.96
Xiaoyao pills plus ﬂuoxetine versus
ﬂuoxetine 2 56/71 54/66 0.97 [0.82, 1.14] 0.69
Danzhi Xiaoyao powder plus
amitriptyline versus amitriptyline 1 38/40 28/38 1.29 [1.05, 1.58] 0.01
Xiaoyao pills plus citalopram versus
citalopram 1 28/30 28/30 1.00 [0.87, 1.14] 1.00
Xiaoyao pills plus doxepin versus
ﬂuoxetine 1 32/35 29/33 1.04 [0.88, 1.22] 0.63
Danzhi Xiaoyao powder plus
clomipramine versus clomipramine 1 30/33 25/33 1.20 [0.96, 1.50] 0.11
Modiﬁed Xiaoyao pills plus
amitriptyline versus ﬂuoxetine 1 29/32 30/32 0.97 [0.84, 1.12] 0.64
Modiﬁed Xiaoyao powder plus
amitriptyline versus amitriptyline 1 31/33 30/33 1.03 [0.90, 1.19] 0.64
Xiaoyao powder plus doxepin versus
doxepin 1 9/12 10/12 0.90 [0.60, 1.36] 0.62
Meta-Analysis 14 386/442 342/432 1.10 [1.04, 1.17] 0.001
Other Outcomes (HAMA Scores, CGI Scores). One trial [10]
showed signiﬁcant beneﬁt on HAMA scores decreased in
favor of combination group after 6 (MD: −2.4 [−4.23,
−0.57]; P = 0.01) weeks treatment.
One trial [10] reported the outcome of CGI scores.
It used modiﬁed DanzhiXiaoyao decoction plus ﬂuoxetine
versus ﬂuoxetine showed better eﬀect on the combination
group (MD: 0.8 [−1.2, −0.4]; P<0.0001).
3.4. Publication Bias. A funnel plot analysis of the 14 trials
comparing xiaoyaosan plus antidepressants to antidepres-
sants on Clinical Comprehensive Eﬀect was generated, and
it showed a signiﬁcant asymmetry (Figure 2).
3.5.AdverseEﬀect. Twenty-fouroutoftwenty-sixtrialsmen-
tioned the adverse eﬀe c te x c e p tt w ot r i a l s[ 22, 24]. Twenty-
four trials reported the twenty-seven speciﬁc symptoms
including diarrhea, dizziness and headache, somnolence, dry
mouth, Bloating, constipation, tachycardia, blurred vision,
insomnia, prolonged QT, naupathia, fatigue, anxiety, tremor,
anorexia, palpitation, asthenia, oscitancy, sweat, akathisia,
tetter, excitation, hypertension, bellyache, dysuria, transami-
nase increased, and sexual dysfunction (Figure 3).
Amitriptyline showed main side eﬀect including dry
mouth, constipation, dizziness, blurred vision, tachycardia,
somnolence and so forth, [8, 9, 14, 18, 22, 25, 32].
Imipramine, chlorimipramine, doxepin showed main side
eﬀect including dry mouth, constipation and other symp-
toms in alimentary canal [11]. Fluoxetine, paroxetine, citalo-
pram showed main side eﬀect including anxiety, insomnia,
headache, naupathia, sexual dysfunction, and tremor, [8, 13,
16, 19–21, 23, 26–28, 30]. Venlafaxine showed main side
eﬀect including dry mouth, sweat, insomnia, headache, and
anxiety, [17, 31].
Four trials [9, 17, 19, 23]r e p o r t e dn os i d ee ﬀect in
the herbal medicine group compared to the antidepressants10 Evidence-Based Complementary and Alternative Medicine
Table 5: Analyses of score of HAMD.
Trials WMD [95% CI] P value
Xiaoyao powder versus antidepressants
Danzhi Xiaoyao powder versus
maprotiline 22 . 3 9 [ −0.55, 5.33] 0.11
Modiﬁed Xiaoyao powder versus
amitriptyline 11 . 1 1 [ −0.21, 2.43] 0.10
Xiaoyao powder versus ﬂuoxetine 1 −3.30 [−6.07, −0.53] 0.02
Meta-Analysis [FEM] 4 0.59 [−0.51, 1.70] 0.29
Meta-Analysis [REM] 4 0.43 [−2.14, 2.99] 0.74
Xiaoyao powder plus antidepressants
versus antidepressants
Xiaoyao pills plus ﬂuoxetine versus
amitriptyline 10 . 0 6 [ −1.50, 1.62] 0.94
Xiaoyao pills plus ﬂuoxetine versus
paroxetine 1 1.88 [0.20, 3.56] 0.03
Danzhi Xiaoyao decoction/powder
plus ﬂuoxetine versus ﬂuoxetine 2 −0.18 [−0.49, 0.13] 0.25
Xiaoyao pills plus imipramine versus
imipramine 1 −0.10 [−2.35, 2.15] 0.93
Xiaoyao pills plus ﬂuoxetine versus
ﬂuoxetine 3 −1.41 [−2.17, −0.65] 0.0003
Danzhi Xiaoyao powder plus
amitriptyline versus amitriptyline 1 −5.84 [−8.76, −2.92] <0.0001
Xiaoyao pills plus citalopram versus
citalopram 1 −0.30 [−2.06, 1.46] 0.74
Xiaoyao pills plus doxepin versus
ﬂuoxetine 1 −0.88 [−1.38, −0.38] 0.0006
Modiﬁed Xiaoyao pills plus
amitriptyline versus ﬂuoxetine 10 . 1 7 [ −1.29, 1.63] 0.82
Xiaoyao powder plus doxepin versus
doxepin 1 −0.80 [−4.84, 3.24] 0.70
Modiﬁed Xiaoyao powder plus
amitriptyline versus amitriptyline 1 −0.76 [−1.16, −0.36] 0.0002
Meta-Analysis [FEM]1 4 −0.51 [−0.71, −0.31] <0.00001
Meta-Analysis [REM]1 4 −0.69 [−1.25, −0.13] 0.02
FEM: ﬁxed eﬀects model, REM: random eﬀects model.
Table 6: Analyses of score of SDS.
Trials WMD [95% CI] P value
Xiaoyao powder versus antidepressants
Danzhi Xiaoyao powder versus maprotiline 1 −1.19 [−10.84, 8.46] 0.81
Guipi Xiaoyao powder versus venlafaxine 1 −5.00 [−7.07, −2.93] <0.00001
Danzyhih Xiaoyao decoction versus ﬂuoxetine 1 −5.14 [−9.54, −0.74] 0.02
Xiaoyao powder versus ﬂuoxetine 1 −1.70 [−4.59, 1.19] 0.25
Meta-Analysis [FEM]4 −3.97 [−5.52, −2.41] <0.00001
Xioayao powder plus antidepressants versus antidepressants
Xiaoyao pills plus ﬂuoxetine versus ﬂuoxetine 1 −3.60 [−4.65, −2.55] <0.00001
g r o u p .T h r e et r i a l sr e p o r t e ds i d ee ﬀect in xiaoyaosan group
including headache, dizziness, and slightly diarrhea [15, 18,
30]. Fifteen out of eighteen trials reported the combination
group has less side eﬀect compare to the antidepressants
group. Twelve trials [7, 15–19, 21, 25, 29–31]m e n t i o n e d
the side eﬀect are signiﬁcant reduced in intervention group
compared to control group. Seven trials [7, 16, 18, 21, 25,
30,31]usedtreatment-emergentsymptomsideeﬀect(TESS)
scale scores, one trial [15] used asberg side eﬀect scale scores,
the rest three trials [17, 19, 29] did not mentioned the tools
they used to evaluate the side eﬀect.
A meta-analysis of four trials [7, 8, 16, 27]w i t h
ﬁve comparison using TESS scale scores showed less side
eﬀect (WMD: −2.51 [−3.18, −1.84]; P<0.00001) usingEvidence-Based Complementary and Alternative Medicine 11
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Figure 2: Funnel plot.
xiaoyaosan plus antidepressants compare to antidepressants
using alone with signiﬁcant heterogeneity (I2 = 87.2%).
There is another trial [18] showed modiﬁed xiaoyao decoc-
tion had less side eﬀect compared to amitriptyline (WMD:
−1.86 [−2.57, −1.15]; P<0.00001).
4. Discussion
Based on this paper and meta-analyses of the outcome on
Clinical Comprehensive Eﬀect, HAMD scores, SDS scores,
HAMA scores, and CGI scores, the prescriptions based
on “xiaoyaosan” including pills, powder, decoction dosage
form using alone or combined with antidepressants may
have beneﬁcial eﬀects on patients with depression. The
prescription xiaoyaosan may have the same eﬀectiveness as
antidepressants at the end point of the treatment with fewer
side eﬀects. The combination group may have signiﬁcant
beneﬁcial eﬀect compared to the antidepressants group
variable on onset time with less side adverse events. We
tried to analysis the trend of “xiaoyaosan”’s eﬀectiveness by
diﬀerent followup time points as well.
The SAS scales scores, TCM-SSD scales scores and the
outcome of the four criteria outcome measurement “cure,
signiﬁcant eﬀective, eﬀective, or ineﬀective” showed that
there are no signiﬁcant diﬀerences between the prescription
group and antidepressants group. Meanwhile the xiaoyaosan
prescriptions [12, 15] using alone may not as eﬀective as
antidepressants after 2 weeks treatment but after 4 or 6
weeks treatment the eﬀectiveness tend to be no signiﬁcant
diﬀerence between two groups. We could clearly tell the
trend from the HAMD scores and the reduced rate [15]
o fH A M Ds c o r e s[ 12, 15]. The SDS scores showed the
xiaoyansanprescriptions aresigniﬁcantlymoreeﬀectiveafter
4w e e k s[ 17] and 6 weeks [19] treatment compared to
antidepressants.
The combination of xiaoyaosan prescription plus antide-
pressants group may have signiﬁcant beneﬁcial eﬀect com-
pared to the antidepressants group. The onset time are
variable may depended on the form of prescription such as
pills and decoctions.
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Figure 3: Side eﬀect of including studies (“xiaoyaosan” versus
antidepressants).
Two meta-analysis on HAMD scores showed signiﬁcant
heterogeneity. It may due to the diﬀerent intervention and
treatment time or the methodology quality. The signiﬁcant
heterogeneity on TESS scales may due to the dosage of the
antidepressants.
According to the twenty-six trials the xiaoyansan pre-
scription group and the combination of xiaoyaosan and
antidepressants group have less adverse events compared
to antidepressants group with signiﬁcant diﬀerences which
were showed by the TESS scales and Asberg side eﬀect scales.
We should consider several limitations before accepting
the ﬁndings of this paper. First, the quality of the included
studies is generally moderate according to the quality
assessment tool for quantitative Studies (Eﬀective Public
Health Practice Project 2007) which was recommended
on the Cochrane Handbook. It also indicated that there
are moderate risk of bias in most of the trials. Due to
inadequate reporting of the allocation sequence, allocation
concealment, blinding, intention to treat analysis and drop
outs account in the majority of trials, it was possible
that there was performance bias and detection bias due12 Evidence-Based Complementary and Alternative Medicine
to patients and researchers being aware of the therapeutic
interventions for the subjective outcome measures. Most
of the trials provided limited descriptions of study design,
randomization were mentioned but without further details
after randomly assignment of patients which do not allow a
proper judgment of the conduct of the trials. Therefore, we
canot draw a conﬁdent conclusion that there are signiﬁcant
beneﬁcial eﬀects in patients with depression on combined
groups or xiaoyaosan prescriptions using alone comparing
to antidepressants. The number of trials identiﬁed limits us
to perform meaningful subgroup or sensitivity analyses to
illuminate robustness of the results in the review. Sixteen
out of twenty-seven trials didnot described the blinding in
details, only two trials [12, 15] used double-dummy in their
study design.
Second, Liu et al. [33] found that some Asian countries
including China publish unusually high proportions of
positiveresults,consideringallofthenineteentrialsincluded
are in Chinese the publication bias possibly existed. We
cannot explore quantitatively the possibility of publication
bias due to the small number of trials.
Third, diﬀerent modiﬁed xiaoyao prescriptions and
diﬀerent form of the prescriptions were used in the trials:
eight trials [7, 8, 11, 16, 20, 27, 28, 31] used ﬁxed
xiaoyaowan throughout the treatment, ﬁve trials used mod-
iﬁed xiaoyaowan, and one trial used modiﬁed xiaoyansan
based on menstruation period of young female [9]. The rest
thirteen trials [10, 13, 14, 18, 19, 21–24, 29, 32] used modi-
ﬁedxiaoyaodecoctionaccordingtosyndromediﬀerentiation
based on Chinese medicine theory, the herbal compound
v a r i e df r o m7t o1 7h e r b s( Table 2). The treatment duration
varied from 30 days to 3 months.
Fourth, the use of composite outcome measures in 26
trials to evaluate overall improvement of symptoms limits
the generalization of the ﬁndings. The classiﬁcation of cure,
signiﬁcant eﬀective, eﬀective, or ineﬀective and the Total
eﬀective rate are not internationally recognized, and these
outcome measurement are vague to interpret the eﬀect. We
suggest future trials to comply with international standards
in the evaluation of treatment eﬀect.
Most of the sample size in the including 26 trials is small
and there is a moderate risk of bias. Further high-quality
studies with larger sample size are needed to conﬁrm the
eﬀectiveness of xiaoyaosan in treating depression. Proper
randomization techniques need to be clearly described and
fully reported. Blinding and double-dummy should be used
and reported clearly although the double-dummy of the
herbal decoction might be very diﬃcult, blinding of patients
and outcome assessors should be used to minimize perfor-
mance and assessment biases. Intention-to-treat principle
and appropriate method for including drop out into data
analyses are also important in the design of the trials.
Since diﬀerent forms of xiaoyaosan prescriptions were used
in patients with depression such as pills and decoctions,
they are likely to have diﬀerent onset time according to
the existed trials. Therefore, future clinical trials may focus
on particular subgroups or large sample size to evaluate
the eﬀect of diﬀerent forms of xiaoyaosan prescriptions on
treating patients with depression. Further randomized trials
with well design and adequate sample size are warranted
to support or refute the positive ﬁndings. Trials should be
reported according to the CONSORT Statement [34].
In general, comparing to three categories (tricyclic-
tertiary amines, nontricyclic, speciﬁc serotonin reup-
take inhibitors (SSRIs)) of antidepressant drugs such as
Amitriptyline, venlafaxine and Fluoxetine, the prescription
based on xiaoyaosan in diﬀerent forms appears to improve
the symptoms with less adverse event. The combination
of xiaoyaosan and antidepressants may have shorter onset
time compare to antidepressants using alone. The mech-
anism [12] may due to the regulating the levels of 5-
HT, CORT, BDNF, IL-6. Since depression may occurred
recurrently with or without treatment, a longer follow-
up period with serial measurement of outcomes after the
treatment is important to determine the eﬀectiveness and
long term eﬀect of the xiaoyaosan prescription. Considering
there are not suﬃcient amount of high-quality trials on
xiaoyaosan prescription treating patients with depression,
the eﬀectiveness of xiaoyaosan prescription need further
rigorous trials to prove.
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